荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

交易中 05-15 09:41:00

89.300

-0.650

-0.72%

最高90.300	最低88.550	成交量13.85万
今开89.500	昨收89.950	日振幅1.95%
总市值503.30亿	流通市值186.26亿	总股本5.64亿
成交额1,242万	换手率0.07%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":89.3,"timestamp":1778809253649,"preClose":89.95,"halted":0,"volume":138500,"delay":0,"changeRate":-0.007226236798221297,"floatShares":208581239,"shares":563608243,"eps":1.487310286479754,"marketStatus":"交易中","change":-0.65,"latestTime":"05-15 09:41:00","open":89.5,"high":90.3,"low":88.55,"amount":12415075,"amplitude":0.019455,"askPrice":89.4,"askSize":2500,"bidPrice":89.25,"bidSize":500,"shortable":3,"etf":0,"ttmEps":2.691452835765709,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1778817600000},"marketStatusCode":2,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":89.95,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":1.107415,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":116.1,"timestamp":1778809256000,"preClose":115.8,"halted":0,"volume":1031500,"delay":0,"premium":"-33.29"}},"requestUrl":"/m/hq/s/09995/tweets","defaultTab":"tweets","newsList":[{"id":"2635722376","title":"荣昌生物(09995)购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722376","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635722376?lang=zh_cn&edition=full","pubTime":"2026-05-15 07:04","pubTimestamp":1778799869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，2026年5月14日，公司与华泰证券订立(1)华泰证券理财产品1号协议，据此公司同意以人民币6000万元的闲置自有资金向华泰证券购买理财产品;(2)华泰证券理财产品2号协议，据此公司同意以人民币7500万元的闲置自有资金向华泰证券购买理财产品;(3)华泰证券理财产品3号协议，据此本公司同意以人民币1.02亿元的闲置自有资金向华泰证券购买理财产品及(4)华泰证券理财产品4号协议，据此公司同意以人民币2.16亿元的闲置自有资金向华泰证券购买理财产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1064130708.USD","688331","BK1161","LU1064131003.USD","LU1969619763.USD","BK0239","BK1574","LU2328871848.SGD","LU2488822045.USD","LU2148510915.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141438080","title":"荣昌生物斥资0.70亿美元购入华侨银行中风险结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=1141438080","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141438080?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:41","pubTimestamp":1778748104,"startTime":"0","endTime":"0","summary":"荣昌生物5月14日披露，其与华侨银行签署结构性存款协议，使用7000万美元闲置自有资金购买“华侨银行有限公司收益联结型结构性存款『增利』系列”产品。\\n\\n此次交易基于公司董事会2026年3月27日通过的决议——批准使用不超过25亿元人民币的闲置自有资金进行现金管理。\\n\\n公司表示，通过投资该类中低风险、收益高于同期定存的产品，可提高闲置资金使用效率；并称已对交易条款进行公平磋商，认为本次投资符合全体股东整体利益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866917","title":"荣昌生物(09995)近期合共购买14.3亿元的银行理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866917","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635866917?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:57","pubTimestamp":1778669853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 公布，于2026年4月28日，公司与浦发银行烟台分行订立浦发银行理财产品1号协议及浦发银行理财产品2号协议，据此公司同意分别以人民币2.2亿元及8000万元的闲置自有资金向浦发银行烟台分行购买理财产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU2148510915.USD","LU2328871848.SGD","BK1583","BK1161","LU1064131003.USD","LU1969619763.USD","LU2488822045.USD","BK1574","688331","LU1064130708.USD","161121","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166498885","title":"异动解读 | 荣昌生物盘中大跌5.12%，巨量解禁压力叠加业绩下滑与板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1166498885","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166498885?lang=zh_cn&edition=full","pubTime":"2026-05-11 09:59","pubTimestamp":1778464757,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大跌5.12%，引起了市场的广泛关注。消息面上，公司将于6月30日迎来约1.928亿股限售股解禁，占总股本的34.16%，相当于当前流通盘翻倍有余，市场对可能出现的集中抛压感到担忧。此外，公司一季度归母净利润环比大幅下降约73%，扣非净利润仍处于亏损状态，基本面压力尚未被市场充分消化。同时，生物科技板块今日整体表现疲软，行业情绪低迷也对个股形成了拖累。综合来看，巨量限售股解禁带来的潜在供给压力、公司短期业绩的大幅下滑以及行业整体的弱势环境，共同导致了荣昌生物股价在盘中的显著下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411573","title":"每周股票复盘：荣昌生物（688331）将召开2025年度暨2026年一季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411573?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:24","pubTimestamp":1778347450,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，荣昌生物报收于123.9元，较上周的129.31元下跌4.18%。本周，荣昌生物5月8日盘中最高价报132.02元。本周关注点公司公告汇总：荣昌生物将于2026年5月14日召开2025年度暨2026年一季度集体业绩说明会。公司公告汇总荣昌生物制药（烟台）股份有限公司将于2026年5月14日下午15:00-16:15通过上证路演中心和第一财经平台，以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2328871848.SGD","LU2148510915.USD","688331","BK0239","LU2488822045.USD","LU1064130708.USD","BK1583","LU1064131003.USD","09995","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633315551","title":"荣昌生物（688331）披露参加‘对话成长’2025年度暨2026年一季度集体业绩说明会公告，5月6日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633315551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633315551?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:05","pubTimestamp":1778076320,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，荣昌生物报收于127.7元，较前一交易日下跌1.25%，最新总市值为720.84亿元。该股当日开盘129.0元，最高130.32元，最低127.5元，成交额达13.71亿元，换手率为6.52%。荣昌生物制药（烟台）股份有限公司近日披露《关于参加“对话成长”2025年度暨2026年一季度集体业绩说明会的公告》。公告显示，公司将于2026年5月14日下午15:00-16:15通过上证路演中心和第一财经平台，以视频和线上文字互动方式召开2025年度暨2026年一季度集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2328871848.SGD","BK1161","LU1064130708.USD","BK1574","LU2488822045.USD","LU1969619763.USD","09995","LU1064131003.USD","LU2148510915.USD","BK1583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120732998","title":"荣昌生物2026年4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1120732998","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120732998?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:48","pubTimestamp":1778057301,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年5月6日发布截至2026年4月30日的股份变动月报表。报告期内，公司股本结构保持稳定，未出现新增发行、回购、注销或库存股份变动。H股方面，上月底与本月底已发行股份保持208,581,239股不变。关于股权激励计划，公司在2022年及2023年分别通过相关A股股票激励计划，授出限制性股票，但本月并无新股实际发行或库藏股份转让，股数较上月未发生变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185348739","title":"异动解读 | 荣昌生物盘中大跌6.51%，一季度业绩环比回落及板块情绪低迷成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1185348739","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185348739?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:49","pubTimestamp":1777859379,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中大跌6.51%，引起了市场的广泛关注。消息面上，公司此前披露的一季度业绩显示，其归母净利润虽同比扭亏为盈，但较上一季度环比大幅下降约73%，且扣非净利润仍为亏损。业绩环比大幅回落，叠加该股前期累计较大涨幅，持续引发市场获利了结压力。此外，南向资金此前已连续净减持该股，资金面承压明显。从板块角度看，今日生物科技行业整体表现偏弱，行业情绪低迷进一步拖累了荣昌生物的股价表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632493046","title":"每周股票复盘：荣昌生物（688331）Q1净利增229.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632493046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632493046?lang=zh_cn&edition=full","pubTime":"2026-05-02 01:26","pubTimestamp":1777656371,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，荣昌生物报收于129.31元，较上周的133.03元下跌2.8%。本周，荣昌生物4月28日盘中最高价报139.98元。股本股东变化截至2026年3月31日，荣昌生物股东户数为1.97万户，较2月28日增加2264户，增幅达12.97%。业绩披露要点荣昌生物2026年一季报显示，主营收入6.56亿元，同比增长24.76%；归母净利润3.28亿元，同比上升229.06%；扣非净利润-3499.1万元，同比改善86.12%；负债率为46.66%，毛利率为82.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU2328871848.SGD","LU2148510915.USD","688331","BK0239","LU2488822045.USD","LU1064130708.USD","BK1583","LU1064131003.USD","09995","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578474","title":"荣昌生物（688331）2026年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631578474?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:54","pubTimestamp":1777503282,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期荣昌生物发布2026年一季报。根据财报显示，荣昌生物营收净利润同比双双增长。截至本报告期末，公司营业总收入6.56亿元，同比上升24.76%，归母净利润3.28亿元，同比上升229.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161848987","title":"荣昌生物2026年第一季度营收6.56亿元，非GAAP净利润3.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161848987","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161848987?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:43","pubTimestamp":1777383794,"startTime":"0","endTime":"0","summary":"据公司披露，荣昌生物2026年第一季度实现营业收入约6.56亿元，同比增长24.76%。同期非GAAP净利润约3.28亿元，而上年同期则为净亏损约2.54亿元，经营表现大幅好转。经营活动产生的现金流量净额约0.11亿元，相较于上年同期的-1.88亿元也显著改善。报告期内，研发投入约2.10亿元，同比下降36.19%，占营业收入的31.98%，较去年同期水平下降30.55个百分点。研发支出减少主要与产品技术授权等因素相关，也在一定程度上推动了公司整体利润转正。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荣昌生物2026年第一季度营收6.56亿元，非GAAP净利润3.28亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175332581","title":"荣昌生物2025年营收同比增长89.5%至32.42亿元，核心产品驱动扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1175332581","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175332581?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:51","pubTimestamp":1777366299,"startTime":"0","endTime":"0","summary":"荣昌生物在截至2025年12月31日止年度实现收入32.42亿元人民币，较2024年的17.10亿元增长89.5%。报告期内毛利从13.67亿元增长至28.16亿元，年内收益7.10亿元，而2024年同期为亏损14.68亿元，盈利水平大幅改善。综合来看，荣昌生物在2025年度依靠创新药物商业化与多条研发管线的进展实现营收和利润的同步提升，显示出其在自身免疫及肿瘤等领域的积累正逐步转化为市场份额与财务回报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"荣昌生物2025年营收同比增长89.5%至32.42亿元，核心产品驱动扭亏为盈","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137868631","title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1137868631","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137868631?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:48","pubTimestamp":1777366101,"startTime":"0","endTime":"0","summary":"4月28日，$荣昌生物(09995)$公告称，2026年第一季度实现营业收入6.56亿元，同比增长24.76%；归属于上市公司股东的净利润为3.28亿元，同比扭亏为盈。业绩变动主要系商业化产品销售收入持续增加，以及产品技术授权导致研发投入减少，认股权证公允价值变动所致。小财注：公司Q1净利润3.28亿，2025年Q4净利润12.6亿，据此计算，Q1净利润环比下降73%。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物：第一季度净利润为3.28亿元，同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1969619763.USD","LU1064130708.USD","BK1574","LU1064131003.USD","09995","BK1161","BK0239","LU2148510915.USD","LU2488822045.USD","LU2328871848.SGD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397093","title":"荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397093","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:04","pubTimestamp":1777298696,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，荣昌生物报收于135.05元，较前一交易日上涨1.52%，最新总市值为762.33亿元。近日，荣昌生物发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00参加由上海证券交易所组织举办的上述集体业绩说明会，通过上证路演中心网络文字互动方式与投资者交流。公司将就2025年度经营成果、财务状况等投资者关注的问题进行回应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1191","LU1969619763.USD","BK0239","LU1064130708.USD","BK1583","LU2148510915.USD","688331","LU1064131003.USD","LU2488822045.USD","BK1574","09995","01477","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009846","title":"汇添富基金增持荣昌生物(09995)7.9万股 每股作价约113.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009846","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629009846?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:09","pubTimestamp":1777028987,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，汇添富基金增持荣昌生物(09995)7.9万股，每股作价113.7788港元，总金额约为898.85万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424191020_91579.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","LU2148510915.USD","LU2328871848.SGD","BK1583","BK1161","LU1064131003.USD","LU1969619763.USD","LU2488822045.USD","BK1574","EWH","688331","LU1064130708.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828474.EUR","DRIP","06978","BK1574","BWET","DRLL","OILT","USE","GUSH","DIG","BNO","LU2242644610.SGD","LU2097828631.EUR","BK1161","DBO","HK0000165453.HKD","09995","ERX","OILU","VDE","01801","USL","03692","USOI","LU2097828714.EUR","DBE","01530","OIH","BK1593","LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","VXUS","LU2328871848.SGD","UGA","LU0502904849.HKD","159992","BK4585","BK1589","BK1191","LU0455707207.USD","PXJ","BK4570","LU2097828557.USD","DBC","OILK","IEO","BK1583","DUG","IXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101463778","title":"异动解读 | 荣昌生物盘中大跌5.19%，多重利好兑现后股价高位回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1101463778","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101463778?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:45","pubTimestamp":1776908718,"startTime":"0","endTime":"0","summary":"荣昌生物（09995.HK）今日盘中股价出现大幅下跌，跌幅达5.19%，引起市场关注。消息面上，公司近期利好密集释放，包括已收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款，以及其全球首创PR-ADC载荷回收平台在AACR大会上披露的超预期核心数据。然而，在前期A股股价一周内涨幅达10.8%、触及近一年新高后，这些利好因素已被市场充分消化。与此同时，南向资金近20个交易日累计净减持467万股，显示出资金持续流出的态势。综合来看，在前期涨幅较大、利好已充分释放叠加资金持续流出的背景下，公司港股股价延续了高位回调的态势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703962","title":"百济、信达、贝达、荣昌生物...盈利Biotech增至17家","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703962","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703962?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:54","pubTimestamp":1776772440,"startTime":"0","endTime":"0","summary":"Biotech似乎终于集体熬到了“上岸”时刻。其中最受关注的自然是百济和信达。百济成立15年后，2025年归母净利润达到14.22亿元；信达生物实现近8.14亿元净利润，正式扭亏为盈。百济神州、微芯生物、迈博药业、信达生物、上海谊众、贝达药业、艾力斯等公司的产品销售收入占比都超过90%。荃信生物2025年净利润3.07亿元，8.07亿元总营收里，7.23亿元来自BD收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-04-21/doc-inhvhmhw6117856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4581","LU1064130708.USD","XBI","BK1583","BK4585","BK1574","LU2148510915.USD","LU2328871848.SGD","BK0239","09995","688331","BK1161","LU1969619763.USD","LU2488822045.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377970","title":"万家基金黄兴亮旗下万家行业优选一季报最新持仓，重仓荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629377970?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:23","pubTimestamp":1776720184,"startTime":"0","endTime":"0","summary":"证券之星消息，4月21日万家基金旗下黄兴亮管理的万家行业优选混合型基金(LOF)公布一季报，近1年净值增长率21.98%。与上一季度相比，该基金前十大重仓股新增科大讯飞；其中荣昌生物持仓占比8.84%，为该基金第一大重仓股；圣邦股份等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100010049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","LU1064131003.USD","LU1969619763.USD","688331","LU2328871848.SGD","09995","BK1583","LU2488822045.USD","BK0239","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275136","title":"每周股票复盘：荣昌生物（688331）获艾伯维6.5亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275136","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275136?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:30","pubTimestamp":1776540626,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，荣昌生物报收于150.11元，较上周的135.48元上涨10.8%。本周，荣昌生物4月16日盘中最高价报156.79元，股价触及近一年最高点。荣昌生物当前最新总市值847.34亿元，在生物制品板块市值排名1/51，在两市A股市值排名235/5198。公司公告汇总荣昌生物制药（烟台）股份有限公司宣布，已收到艾伯维就RC148独家授权许可协议支付的6.5亿美元首付款。该协议于2026年3月10日生效，艾伯维获得了RC148在大中华区以外地区的开发、生产和商业化独家权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1583","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","LU1969619763.USD","LU1064131003.USD","688331","09995","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1138},{"period":"1month","weight":-0.1702},{"period":"3month","weight":0.1202},{"period":"6month","weight":0.0527},{"period":"1year","weight":1.1753},{"period":"ytd","weight":0.2493}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.02},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1163},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.037139},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}